Recall alert: Some GLP-1 injections recalled over sterility concerns

Some vials of compounded GLP-1 injections have been recalled because the products may not be sterile, federal health officials said.Read more trending newsAccording to the U.S. Food and Drug Administration, Apothecary Pharma is recalling 23 vials of the injectable drugs that were distributed nationwide. The voluntary recall includes 22 vials of compounded tirzepatide, a GLP-1 medication containing the same active ingredient as Mounjaro and Zepbound, Fox News reported. The other vial was a NAD+ injection, according to the news outlet.The Cary, North Carolina-based pharmacy was previously reprimanded by the FDA for “serious deficiencies” in its practices, according to the Los Angeles Times.Apothecary Pharma first initiated a voluntary recall of tirzepatide injections on Sept. 24 for “lack of assurance of sterility,” USA Today reported, citing an FDA notice.These GLP-1 injections have been recalled nationwide. Here's the affected medication and reasoning behind the recall. https://t.co/0G